Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06611696

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis (ARRIA)

Avacopan With Short-term Reduced-dose Glucocorticoids vs Reduced-dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-associated Vasculitis

Sponsor: Chiba University

Conditions ANCA Associated Vasculitis (AAV)

Interventions Avacopan, prednisolone and rituximab Prednisolone and rituximab

Updated 4 times since 2024 Last updated: May 1, 2025 Started: Nov 15, 2024 Primary completion: Mar 31, 2027 Completion: Sep 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06611696, this PHASE4 trial focuses on ANCA Associated Vasculitis (AAV) and remains actively recruiting participants. Sponsored by Chiba University, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE4
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE4
Oct 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiba University
International University of Health and Welfare
Kissei Pharmaceutical Co., Ltd.

Data source: Chiba University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asahi, Japan , Bunkyoku, Japan , Chiba, Japan , Chuo-shi, Japan , Hiragi, Japan , Ichihara, Japan , Kamogawa, Japan , Kawagoe, Japan , Kawasaki, Japan , Maebashi, Japan and 10 more locations